Compare Intuit Inc. (INTU) vs Novartis AG (NVS) Price & Performance

Intuit Inc.Trade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

Intuit Inc. vs Novartis AG — how do they compare? Intuit Inc. trades at $293.66 (market cap $80.37B), while Novartis AG trades at $149.81 (market cap $290.25B). The key difference: Novartis AG is far larger — about 3.6× Intuit Inc.'s market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.

	INTU	NVS
Market Cap	$80.37B	$290.25B
Sector	Technology	Health
52-Week High	$807.39	$168.62
52-Week Low	$255.07	$113.50
Enterprise Value	$78.83B	$330.27B
Dividend Yield	1.63%	3.17%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Intuit Inc.

Intuit (INTU) trades at $291.09, down 1.26% over the past day, amid mixed technical signals and ongoing legal scrutiny. The stock shows strong fundamentals with revenue growth from $18.83B in 2025 to a projected $20.9B in 2026, net income margin improving to 21.91%, and consistent earnings beats. However, recent news highlights a 20% stock drop and multiple securities fraud investigations related to TurboTax pricing issues, creating investor uncertainty despite a bullish analyst consensus.

The outlook for INTU is cautiously optimistic given its robust financial health and AI-driven growth initiatives, but near-term risks from legal challenges and market sentiment could pressure the stock. Investors should weigh the company's solid profitability and upward earnings trajectory against potential volatility from ongoing investigations and competitive pressures in the fintech software space.

Novartis AG

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INTU

View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 22 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About Intuit Inc.

Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.